The presence of P2U purinoceptor in human granulosa-luteal cells (hGLCs) indicates a potential role of ATP in regulating ovarian function. In this study an inhibitory effect of ATP on hCG-induced cAMP production was observed. Extracellular ATP has been shown to activate protein kinase C (PKC) after binding to a purinoceptor. To understand the role of PKC in mediating ATP action, hCG-stimulated cAMP level was examined in the presence of the PKC activator, 1 mol/L phorbol 12-myristate 13-acetate (PMA), or the PKC inhibitor, 1 mol/L staurosporin or 1 mol/L bisindolylmaleimide I. PMA, like 10 mol/L ATP, significantly reduced hCG-evoked cAMP production. In addition, the inhibitory effect of ATP was reversed by staurosporin and bisindolylmaleimide I. To further investigate the involvement of PKC isoforms in mediating the inhibitory effect of ATP, the presence of PKC isoforms in cultured hGLCs was examined by Western blot using monoclonal antibodies against specific isoforms. Translocation of PKC isoforms from cytosolic fraction to membrane fraction was studied to identify the active PKC isozymes subsequent to ATP treatment. The change in PKC isoform in PKC-depleted cells (achieved by exposure to PMA for 18 h) was also examined. Our results demonstrated the presence of PKC␣, -␦, -, and -isoforms in hGLCs and the translocation of PKC␣ subsequent to ATP treatment. In PKCdepleted cells the PKC␣ level was reduced, and no significant effect of ATP on hCG-stimulated cAMP production was observed. To our knowledge, this is the first demonstration of PKC isoforms in hGLCs and the involvement of activated PKC in mediating the antigonadotropic effect of extracellular ATP. Taken together, these results further support a role of this neurotransmitter in regulating human ovarian function. (J Clin Endocrinol Metab 86: 3237-3242, 2001) 
A TP IS RELEASED from cells such as platelets or coreleased with neurotransmitter granules from autonomic nerves by exocytosis (1) . ATP has been shown to participate in various types of physiological responses, including secretion, membrane potential, cell proliferation, platelet aggregation, neurotransmission, cardiac function, and muscle contraction (2) (3) (4) (5) (6) . It is tempting to speculate that the coreleased ATP from autonomic nerve endings in the ovary may play a role in regulating ovarian function. We have reported previously that the P2U purinoceptor was expressed in human granulosa-luteal cells (hGLCs) (7), further supporting a physiological role of ATP in the human ovary.
After binding to a G protein-coupled P2 purinoceptor, extracellular ATP activates phospholipase C and phosphatidylinositol hydrolysis, generating diacylglycerol and inositol 1,4,5-triphosphate, which stimulate protein kinase C (PKC) and cytosolic calcium mobilization, respectively (2, 7, 8) . The PKC family, a group of widely distributed serine/ threonine kinases, mediates intracellular signaling of numerous cellular regulators including hormones, neurotransmitters, and growth factors (9, 10) . Thirteen isozymes have been identified and categorized into four subclasses: 1) conventional PKCs (␣, ␤I, ␤II, and ␥), which are regulated by diacylglycerol, phosphatidylserine, and Ca 2ϩ ; 2) novel PKCs (␦, ⑀, , and ), which are regulated by diacylglycerol and phosphatidylserine; 3) atypical PKCs (, , and ), whose regulation has not been clearly established; and 4) a fourth subfamily, and (11) (12) (13) . It is noteworthy to address that multiple and various PKC isoforms are present in the ovary of different species. In the rabbit corpus luteum, ␣, ␤, and ␦ isoforms of PKC are identified (14) , whereas porcine corpora lutea contains ␣ and ␤ (15) . Western blot analysis reveals that bovine corpus luteum expresses ␣ and ␦ (16) .
In the present study we demonstrated that ATP reduced hCG-induced cAMP accumulation in hGLCs. To further define the mechanism of action of ATP, we examined the effect of PKC on hCG-induced cAMP production, the expression of PKC isozymes, and the translocation of PKC isozymes subsequent to ATP treatment.
ton, Canada). Bisindolylmaleimide I, a PKC inhibitor, was obtained from Calbiochem (Cedarlane, Hornby, Ontario, Canada).
hGLC culture hGLCs were collected from patients undergoing an in vitro fertilization-embryo transfer program. The use of hGLCs was approved by University of British Columbia clinical screening committee for research and other studies involving human subjects. Granulosa cells were separated from red blood cells in follicular aspirates by centrifugation through Ficoll-Paque, washed, and suspended in DMEM containing 100 U penicillin G/mL, 100 g streptomycin/mL, and 10% FBS as described previously (7) . The cells were plated in culture dishes. Cells were then incubated at 37 C under a water-saturated atmosphere of 5% CO 2 in air for 3 days.
RIA for intracellular cAMP
To determine the effect of ATP on hCG-induced intracellular cAMP accumulation, hGLCs were incubated in serum-free medium containing 0.1% BSA and 0.5 mmol/L 3-isobutyl-1-methylxanthine (Sigma-Aldrich Corp., St. Louis, MO) for 30 min. hGLCs were then treated with hCG (1 IU/mL) in the absence or presence of increasing concentrations of ATP (0.1-100 mol/L) for 20 min. hGLCs were lysed with 100% ethanol. Intracellular cAMP levels were measured using the [ 3 H]cAMP assay system according to the manufacturer's suggested protocol (Amersham Pharmacia Biotech, Oakville, Canada).
Treatment for cAMP assay
To investigate the role of PKC in hCG-evoked cAMP accumulation, hGLCs were treated with 1 IU/mL hCG in the presence or absence of 1 mol/L PMA, a PKC activator, for 20 min. To understand the involvement of PKC in the effect of ATP on hCG-induced cAMP production, hGLCs were treated with ATP plus hCG in the presence or absence of PKC inhibitors (1 mol/L staurosporin or 1 mol/L bisindolylmaleimide I) for 20 min. In this study hGLCs were treated with staurosporin or bisindolylmaleimide I for 15 min before the administration of ATP.
Western blot analysis
To establish the expression of PKC isozymes, hGLCs were washed with ice-cold PBS and lysed with 100 mol/L cell lysis buffer [RIPA; 150 mmol/L NaCl, 50 mmol/L Tris-HCl (pH 7.5), 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 1.0 mmol/L phenylmethylsulfonylfluoride (PMSF), 10 g/mL leupeptin, and 100 g/mL aprotinin] at 4 C for 30 min. The cell lysate was centrifuged at 10,000 ϫ g for 5 min, and the supernatant was collected for Western blot analysis. The amount of protein was quantified using a protein assay kit (Bio-Rad Laboratories, Inc., Richmond, CA) following the manufacturer's protocol. Aliquots (30 g) were subjected to 10% SDS-PAGE under reducing conditions, as previously described (17) . The proteins were then electrophoretically transferred from the gels onto nitrocellulose membranes (Amersham Pharmacia Biotech) according to the procedures of Towbin et al. (18) . These nitrocellulose membranes were probed with mouse monoclonal antibodies directed against specific PKC isozymes (Transduction Laboratories, Lexington, KY) at 4 C for 16 h. After washing, the membranes were incubated with horseradish peroxidase-conjugated goat antimouse secondary antibody, and the signal was visualized using the ECL system (Amersham Pharmacia Biotech), followed by autoradiography.
RT-PCR
In view of the presence of PKC␥, expressed mainly in the nervous system (19) , and as the monoclonal antibody for PKC␥ may cross-react with PKC␣ according to the manufacturer, a set of primers was used to examine the expression of PKC␥, as reported previously (20) . Total ribonucleic acid (RNA) was isolated from hGLCs as previously described (7) . As a positive control, the RNA from human antral gastrin cells was provided by Dr. Buchan (20) . Briefly, 1 g RNA was reverse transcribed into complementary DNA (cDNA) using the First Strand cDNA Synthesis Kit (Pharmacia Biotech, Morgan, Canada). One set of oligonucleotide primers (5-CCCGGCGTAGGCGATTCAGA-3 and 5-TACGTGGATCTCATCTGCTGT-3) (20) was used for PCR to amplify the PKC␥ isoform from hGLCs. PCR reactions were performed in the presence of 10 mmol/L Tris-HCl (pH 8.3), 50 mmol/L KCl, 1.5 mmol/L MgCl 2 , 400 mol/L deoxy-NTPs, 0.25 U Taq DNA polymerase, 2 mol/L primers, and 1 L cDNA template/25 L reaction. Amplification was carried out for 35 cycles with denaturation at 94 C for 45 s, annealing at 59 C for 35 s, extension at 72 C for 45 s, and a final extension at 72 C for 15 min.
Translocation experiment of PKC isozymes
hGLCs were incubated in serum-free medium for 4 h before treatment. To examine the translocation of activated PKC, hGLCs were treated with 10 mol/L ATP for 1 or 5 min. Fractionation of cytosolic and membrane proteins was performed as described previously (21) . In brief, cells were harvested in test buffer [ 
PKC depletion
Long-term treatment with PMA (16 h) results in PKC depletion (22) . In this study hGLCs were pretreated with 1 mol/L PMA for 18 h. Separate studies were then performed to examine the expression of PKC␣ and the effect of ATP on hCG-induced cAMP accumulation in PKC-depleted hGLCs using Western blot analysis and RIA, respectively.
Statistical analysis
Intracellular cAMP levels were shown as picomoles per 2 ϫ 10 5 cells/dish. Data were presented as the mean Ϯ se. Statistical analysis was performed by one-way ANOVA, followed by Tukey's multiple comparison test. Differences were considered significant at P Ͻ 0.05.
Results

Effect of ATP on hCG-induced cAMP production
ATP has been demonstrated to increase intracellular cAMP production by activating adenylate cyclase in several cell systems (23, 24) . To examine the effect of ATP on intracellular cAMP production, hGLCs were treated with hCG in the absence or presence of increasing concentrations of ATP for 20 min. As demonstrated in Fig. 1 , hCG markedly increased the intracellular cAMP level. In contrast, 10 mol/L ATP did not increase intracellular cAMP accumulation in hGLCs compared with that in the control group. This indicates that the P2U purinoceptor expressed in hGLCs is not coupled to adenylate cyclase. Instead, ATP reduced hCGevoked cAMP production in a dose-dependent manner, whereas the maximal effect was reached at 10 mol/L. ATP at 10 mol/L reduced hCG-stimulated cAMP production by 40% compared with hCG treatment alone. Besides, no significant difference was noted between cells treated with 10 and 100 mol/L ATP.
Role of PKC in hCG-induced intracellular cAMP accumulation
Phorbol ester was shown to activate PKC in human ovarian tissue (25) . When hGLCs were treated with 1 mol/L PMA, hCG-stimulated cAMP production was reduced by 30% (Fig. 2) .
To further investigate the role of PKC, hGLCs were treated with ATP plus hCG in the presence or absence of PKC inhibitor (1 mol/L staurosporin or 1 mol/L bisindolylmaleimide I). As shown in Fig. 3 , the inhibitory effect of ATP on hCG-evoked cAMP production was reversed by PKC inhibitors, supporting the active involvement of PKC in the regulation of cAMP production.
Expression of PKC isozymes in hGLCs
Eight antibodies against various PKC isozymes were used for the Western blot analysis. Compared with the positive control, five (␣, ␥, ␦, , and ) isoforms were identified by showing bands of the expected sizes (Fig. 4) . PKC␤, -⑀, and -were absent in hGLCs. In the present study Jurkat cells were used as the positive control for PKC, whereas rat brain was used as the positive control for the rest of the PKC isoforms.
Considering that the monoclonal antibody against PKC␥ may cross-react with PKC␣, and PKC␥ is found mainly in the nervous system (19), RT-PCR was performed to examine the presence of PKC␥ in hGLCs. Our results demonstrated the absence of PKC␥ in hGLCs. Primers specific for PKC␥ amplified a band of the expected size from the positive control, human antral gastrin cells, but not from hGLCs (data not shown). This observation ruled out the existence of PKC␥ in hGLCs.
Translocation of PKC␣ from cytosolic to membrane fraction
Activation of PKC is associated with a translocation of the enzyme from the cytosolic fraction to the plasma membrane (21) . In the present study hGLCs were treated with 10 mol/L ATP for 1 or 5 min. Of the four PKC isoforms, only PKC␣, which is found mainly in the cytoplasm, was noted to have increased expression in the membrane fraction and reduced expression in the cytosolic fraction after treatment (Fig. 5) . The translocation of the PKC␣ isoform to the plasma membrane was accompanied by a decrease in the amount of PKC␣ in the cytosolic fraction.
Effect of PKC depletion
After treatment with PMA for 18 h, the PKC␣ isozyme in hGLCs was significantly down-regulated compared with that in the control group (Fig. 6A ). There was no significant effect of ATP on hCG-stimulated cAMP production after PMA pretreatment for 18 h (Fig. 6B) .
Discussion
The presence of P2U purinoceptor in hGLCs suggests a role of extracellular ATP in the human ovary (7). We reported previously that ATP exerted an antigonadotropic action by reducing hCG-induced progesterone levels (26) . To examine the underlying mechanism, we demonstrated in this study that PKC was associated with the inhibitory effect of ATP on hCG-stimulated cAMP accumulation. The presence of PKC␣ in hGLCs and its translocation from the cytosolic fraction to the membrane fraction indicate a role of activated PKC␣ in mediating the action of ATP on hCG-induced cAMP production.
cAMP is well established in mediating hCG actions such as progesterone production in the ovary. PGF 2␣ , an antigonadotropic agent, inhibits gonadotropin-induced progesterone production in hGLCs via reducing gonadotropinstimulated cAMP accumulation (27) . In this study we demonstrated that ATP has an inhibitory effect on reducing hCG-induced cAMP production, further supporting a regulatory role of extracellular ATP in ovarian function. Extracellular ATP has been shown to regulate cellular function through activation of PKC (1-3). It appears that PKC may have dual actions by providing positive forward actions as well as negative feedback in controlling various signaling steps (28, 29) . We have recently reported that ATP is able to induce cytosolic calcium oscillations, and that activated PKC can negatively regulate ATP-evoked calcium mobilization from both intracellular stores and extracellular influx in hGLCs (30) . In this study the forward action of PKC in mediating the ATP effect on hCG-induced cAMP accumulation was demonstrated using a PKC activator and PKC inhibitors. PKC isozymes consist of single polypeptide chains, each containing an amino-terminal regulatory region and a carboxyl-terminal kinase domain (31) . Phorbol esters cause activation of conventional and novel PKC isozymes through binding to the regulatory region (28) . In the present study PMA mimicked the effect of ATP by reducing the hCG-induced cAMP production. Staurosporin, which is a potent PKC inhibitor (32) , and bisindolylmaleimide I (33), which is a selective PKC inhibitor for PKC␣, -␤, and -␥, effectively reversed the inhibitory action of ATP in hCGevoked cAMP production. These observations support the idea that PKC plays a role in mediating ATP action in the human ovary. Multiple and various PKC isoforms have been shown in the ovary of different species (14 -16) . In the present study we identified the presence of PKC␣, -␦, -, and -isoforms in hGLCs. PKC subspecies are expressed specifically in certain tissue (19) . PKC␥ appears to be present predominantly in the nervous system, such as the brain and spinal cord (34) . Outside of the nervous system, PKC␥ is identified in human antral gastrin cells (20) . Based on the RT-PCR results, we ruled out the presence of this isoform in hGLCs. We reported previously that 10 mol/L ATP induced cytosolic calcium oscillations in hGLCs (7), implicating the activation of a calcium-dependent PKC subsequent to ATP exposure. Our results demonstrated that the PKC␣, a calcium-dependent PKC isoform, was translocated from the cytosolic fraction to the membrane fraction after ATP treatment, indicating that PKC␣ is involved in the antigonadotropic action of ATP in hGLCs.
Long-term exposure to phorbol esters causes downregulation of PKC activity associated with proteolysis of PKC. Proteases, such as calpain or serine protease, act at the hinge region between the regulatory and catalytic domains of PKC (35) (36) (37) . Prolonged exposure to PMA (16 h) has been demonstrated to down-regulate PKC activity in hGLCs (22) . In this study long-term treatment of hGLCs with PMA downregulated the expression of PKC␣ (Fig. 6) , which was shown to be activated by ATP (Fig. 5) . The effect of ATP on hCGstimulated cAMP accumulation was lost in PKC-depleted cells, indicating the involvement of PKC␣ in reducing hCGinduced cAMP production.
The observation that ATP inhibited intracellular cAMP responses to hCG through activation of PKC leads us to speculate several potential action sites of activated PKC. Considering the presence of potential PKC phosphorylation sites in the third intracellular loop and at the C-terminal of the LH/hCG receptor, this receptor may be affected by activated PKC after ATP treatment. These intracellular regions of LH/hCG receptor are coupled to the G s protein, suggesting that active PKC may be involved in the dissociation of the LH/hCG receptor from the G s protein (38, 39) . With respect to receptor-coupled G proteins, several studies have shown that phorbol ester can regulate G protein-mediated responses (40 -42) , indicating that the LH/hCG-coupled G s protein may be inhibited by activated PKC in hGLCs. G proteincoupled adenylate cyclase is associated with cAMP accumulation. PKC has been demonstrated to alter the activity of adenylate cyclase (43) , pointing out another possible site of action for activated PKC subsequent to ATP treatment in hGLCs. cAMP phosphodiesterase causes degradation of cAMP and thus alters intracellular cAMP accumulation. Stimulation of cAMP phosphodiesterase via PKC has been reported in cultured hGLCs (44) , suggesting one more factor that may be associated with the regulation of cytosolic cAMP levels.
In conclusion, our results demonstrated that 1) extracellular ATP has an inhibitory effect on hCG-stimulated cAMP accumulation; 2) the PKC␣, -␦, -, and -isoforms are present in hGLCs; 3) PKC␣ is translocated from the cytosolic fraction to the membrane subsequent to ATP treatment; and 4) PKC is involved in mediating the antigonadotropic action of extracellular ATP. Taken together, these results further support a role of this neurotransmitter in ovarian steroidogenesis.
